Navigation Links
Zimmer Holdings Announces OMeGA Graduate Medical Education Grant Recipients
Date:10/28/2009

WARSAW, Ind., Oct. 28 /PRNewswire-FirstCall/ -- Zimmer Holdings, Inc. (NYSE: ZMH; SWX: ZMH) today announced that OMeGA Medical Grants Association LLC (OMeGA) has chosen its 2009 grant recipients. OMeGA is the newly formed third party administrator for graduate medical education to which Zimmer committed $2 million in funding for educational grants for the 2009-2010 academic year.

OMeGA received more than 250 applications for its fellowship and residency grants. This year, utilizing Zimmer's donation, OMeGA will fund 44 fellowship grants up to $75,000 each, representing 29% of programs requesting grants. Fellowship grants were allocated in all sub-specialty categories: Adult Reconstruction; Foot and Ankle; Hand Surgery; Oncology; Pediatrics; Shoulder and Elbow; Spine; Sports Medicine; and Trauma. OMeGA will also fund 21 residency grants up to $5,000 each at both academic institutions and community hospitals.

"High quality education programs are essential to encourage medical graduates to enter the field. We are proud to collaborate with OMeGA to support institutions and programs that will help assure improvements in patient care," said David Dvorak, President and Chief Executive Officer of Zimmer Holdings. "At Zimmer, we are committed to providing surgeons with outstanding training programs. Through our contributions to OMeGA, we are able to offer needed support to aspiring surgeons."

In November 2008, Zimmer became the founding supporter of OMeGA, an independent organization created by the American Orthopaedic Association (AOA). The OMeGA board and review committee members are free from conflicts of interest: they do not have financial interests in any orthopaedic medical device manufacturer (for the previous two years) or leadership roles (i.e., financial decision-making) in orthopaedic fellowship or residency
'/>"/>

SOURCE Zimmer Holdings, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Zimmer Launches New Medical Education and BioSkills Training Program
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2009 Results
3. Zimmer Holdings to Present at 29th Annual Cowen and Co. Health Care Conference
4. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Third Quarter 2008 Results
5. Zimmer Holdings, Inc. Announces Agreement to Acquire Abbott Spine, an Innovator in Spinal Technology
6. Zimmer Holdings to Present at William Blair Growth Stock Conference
7. Zimmer Holdings to Present at Wachovia Healthcare Conference
8. Zimmer Holdings Announces Support for Elimination of Super-Majority Voting Requirements
9. Zimmer Announces Settlement of Federal Investigation
10. Zimmer and Tutogen Announce Agreement for International Distribution of Biological Products
11. Tutogen Medical, Inc. and Zimmer Holdings, Inc. Announce Agreement for International Distribution of Biological Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Calabasas, CA (PRWEB) July 10, 2014 ... academic institutions and professional associations, addressed the challenges of ... & Medical Device Industries” through strategic sourcing. Describing the ... ) with the Supply Chain Management Institute ( SCMI) ... the event on June 24 at the Kroc Institute ...
(Date:7/10/2014)... , July 10, 2014  Kainos Capital, a ... brands, today announced that it has acquired the Slim-Fast ... in the business. Terms of the transaction were not ... and meal replacement business that markets ready-to-drink shakes, powders, ... North America and in the ...
(Date:7/10/2014)... OAKS, Calif., July 10, 2014   Ceres, Inc ... and seed company, announced today financial results for the ... update on its business. Ceres reported that ... in product performance this growing season in Brazil, which ... affected the company,s sorghum evaluation areas for part of ...
(Date:7/10/2014)... June 17, 2014 Using microscopic polymer light ... gases, researchers at MIT,s Quantum Photonics Laboratory have ... in the parts-per-billion range. Optical sensors are ideal ... high signal-to-noise ratio, compact, lightweight nature, and immunity ... sensors had been developed before, the MIT team ...
Breaking Biology Technology:Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 2Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 3Biotech & Biopharm Supply Chain Management Executives Launch BSMA in San Diego 4Kainos Capital Acquires Slim-Fast From Unilever 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 2Ceres Announces Fiscal Third Quarter 2014 Financial Results 3Ceres Announces Fiscal Third Quarter 2014 Financial Results 4Ceres Announces Fiscal Third Quarter 2014 Financial Results 5Ceres Announces Fiscal Third Quarter 2014 Financial Results 6Ceres Announces Fiscal Third Quarter 2014 Financial Results 7Ceres Announces Fiscal Third Quarter 2014 Financial Results 8Ceres Announces Fiscal Third Quarter 2014 Financial Results 9Swell new sensors 2
... SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS ... ... if (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... var shortURL = ""; BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results ...
... 2010 Savara Inc., an inhalation product development company, ... its Board of Directors. In 1983 Mr. ... he guided the growth of that organization to over ... the largest clinical contract research organizations in the world. ...
... N.J., Nov. 8, 2010 Omthera Pharmaceuticals, ... today announced the initiation of a randomized, ... the bioavailability of Epanova™, Omthera,s lead compound ... in comparison to Lovaza®, the leading prescription ...
Cached Biology Technology:YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 2YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 3YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 4YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 5YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 6YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 7YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 8YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 9YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 10YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 11YM BIOSCIENCES REPORTS SIGNIFICANT RESPONSE RATES IN ANEMIA, SPLENOMEGALY, AND CONSTITUTIONAL SYMPTOMS FROM THE PHASE I/II TRIAL OF ITS JAK1/JAK2 INHIBITOR, CYT387, IN MYELOFIBROSIS 12Savara Announces Appointment of Pharmaceutical Veteran to Board of Directors 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 2Omthera Pharmaceuticals, Inc. Announces Initiation of the ECLIPSE Trial: Epanova Compared to Lovaza In a Pharmacokinetic Single-dose Evaluation 3
(Date:7/10/2014)... BLUE BELL, Pa. , July 2, 2014  Unisys ... The Netherlands , Unisys Nederland N.V., today announced that ... (DJI) to deliver, implement and manage a new Basic Provision ... . Unisys won the contract with a ... for identity management software. The term of the contract is ...
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
(Date:7/10/2014)... belongs to the large, mainly tropical flowering plant family ... in the family rely on bees for their pollination. Only ... or vertebrates. The flowers of Axinaea appear in ... petals of the different species are pink, yellow, orange or ... the contrasting colours of their bulbous appendages. The pollination mechanism ...
Breaking Biology News(10 mins):Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2Novel type of bird pollination mechanism discovered in South America 2
... historic fish, with an intriguing past, now has had ... the genetic changes that accompanied the adaptation from an ... led by Chris Amemiya, PhD, Director of Molecular Genetics ... and Professor of Biology at the University of Washington, ...
... has the ability to ward off viruses by activating a ... chain reaction that disrupts the levels of cholesterol required in ... discovered by researchers in molecular microbiology and immunology at the ... development of therapies to fight a variety of viral infections. ...
... a long time to produce in the ovary, and thus ... been theorized that the body has mechanisms to help the ... the right time in order to maximize the chance of ... Jianjun Sun has shed light on how successful ovulation and ...
Cached Biology News:Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 2Genome sequencing of the living coelacanth sheds light on the evolution of land vertebrate 3University of Southern California scientists reveal natural process that blocks viruses 2Reproductive tract secretions elicit ovulation 2Reproductive tract secretions elicit ovulation 3
... product contains 5 ml Dynabeads Tosylactivated (4.5 ... (tosyl) reactive groups. For coupling of antibodies ... on initial coupling with covalent binding of ... sulphydryll groups (SH)) occurringovernight. Coupling reactions can ...
Carrier-Free Recombinant Human Flt-3/Flk-2 Ligand (Flt3/Flk2 Ligand, Flt3L, Flt3-L, Flk2L, Flk2-L) 100 ug...
... II inhibitor (IC50 = 59.2 M). ... H 32 O 13 MolWeight: ... RT CAS: ... Soluble to 100 mM in DMSO ...
NAP-2 (5C7)...
Biology Products: